Atypical diffuse bilateral cystic lung changes secondary to erlotinib treatment in a patient with metastatic non-small cell lung carcinoma: A case report and literature review.

Autor: Ansari J; Department of Oncology, Prince Sultan Military Medical City, Riyadh 11159, Saudi Arabia., Batubara E; Department of Pulmonology, Prince Sultan Military Medical City, Riyadh 11159, Saudi Arabia., Ali M; Department of Oncology, Prince Sultan Military Medical City, Riyadh 11159, Saudi Arabia., Farrag A; Department of Oncology, Prince Sultan Military Medical City, Riyadh 11159, Saudi Arabia.; Clinical Oncology Department, Assiut University Hospital, Assiut University, Asyut 71515, Egypt., Bashir F; Department of Oncology, Prince Sultan Military Medical City, Riyadh 11159, Saudi Arabia., Farghaly HR; Department of Nuclear Medicine Division, Prince Sultan Military Medical City, Riyadh 11159, Saudi Arabia., Ali AM; Department of Oncology, Prince Sultan Military Medical City, Riyadh 11159, Saudi Arabia.; Medical Oncology Department, South Egypt Cancer Institute, Assiut University, Asyut 71515, Egypt., Shaukat A; Department of Oncology, Prince Sultan Military Medical City, Riyadh 11159, Saudi Arabia.
Jazyk: angličtina
Zdroj: Molecular and clinical oncology [Mol Clin Oncol] 2018 Jul; Vol. 9 (1), pp. 92-95. Date of Electronic Publication: 2018 May 04.
DOI: 10.3892/mco.2018.1620
Abstrakt: Erlotinib is a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor (EGFR) mutations. The response rate to erlotinib is ~60% and the incidence of erlotinib-induced interstitial lung disease (ILD) is ~1-4%. The Response Evaluation Criteria in Solid Tumours (RECIST) tool is commonly used to assess response to erlotinib; however, evaluation of response and subsequent progression in the presence of atypical cystic lung changes may be challenging. We herein present a rare case of diffuse cystic lung changes secondary to erlotinib treatment in a patient with EGFR mutation-positive metastatic NSCLC. Challenges in assessing atypical tumour response to erlotinib, pitfalls in using RECIST and differential diagnosis of TKI-related ILD are discussed in detail.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje